GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Research & Development

NeoImmuneTech (XKRX:950220) Research & Development : ₩10,617.29 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. NeoImmuneTech's Research & Development for the three months ended in Dec. 2023 was ₩0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was ₩10,617.29 Mil.

NeoImmuneTech Research & Development Historical Data

The historical data trend for NeoImmuneTech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoImmuneTech Research & Development Chart

NeoImmuneTech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Research & Development
8,592.47 22,704.39 38,420.99 - -

NeoImmuneTech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 10,617.29 -

NeoImmuneTech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩10,617.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoImmuneTech  (XKRX:950220) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

NeoImmuneTech Research & Development Related Terms

Thank you for viewing the detailed overview of NeoImmuneTech's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

NeoImmuneTech (XKRX:950220) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Research & Development
Comparable Companies
XKRX:215380 XKRX:322970 XKRX:343090 XKRX:283100 XKRX:446440 XKRX:072520 XKRX:251280 XKRX:179530 XKRX:344860 XKRX:208340 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850
Website
http://www.neoimmunetech.com
NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.

NeoImmuneTech (XKRX:950220) Headlines

No Headlines